REFERENCES
- Weatherall DJ, Clegg JB. Inherited hemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001; 79(8):704–712.
- Kontoghiorghes GJ, Eracleous E, Economides Ch, Kolnagou A. Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinations. Curr Med Chem. 2005; 12(23):2663–2681.
- World Health Organization. Community control of hereditary anaemias. Bull. WHO. 1983; 61(1):63–80.
- Kontoghiorghes GJ. Ethical issues and risk/benefit assessment on iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and cost of deferasirox. Hemoglobin. 2008; 32(1–2):1–15.
- Zurlo MG, De Stefano P, Borgna-Pignatti C, Survival and causes of death in thalassaemia major. Lancet. 1989; 2(8653):27–30.
- Kyriacou K, Michaelides Y, Senkus R, Ultrastructural pathology of the heart in patients with β-thalassemia major. Ultrastruct Pathol. 2000; 24(2):75–81.
- Aessopos A, Farmakis D, Hatziliami A, Cardiac status in well-treated patients with thalassaemia major. Eur J Haematol. 2004; 73(5):359–366.
- Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000; 355(9220):2051–2052.
- Borgna-Pignatti C, Cappellini MD, De Stefano P, Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006; 107(9):3733–3737.
- Telfer P, Coen PG, Christou S, Survival of medically treated thalassaemia patients in Cyprus. Trends and risk factors over the period 1980–2004. Haematologica. 2006; 91(9):1187–1192.
- Kuliev A, Rechitsky S, Verlinsky O, Preimplantation diagnosis and HLA typing for hemoglobin disorders. Reprod Biomed Online. 2005; 11(3):362–370.
- Andreani M, Nesci S, Lucarelli G, Long-term survival of ex-thalassemic patients with persistent mixed chimerism following bone marrow transplantation. Bone Marrow Transplant. 2000; 25(4):401–404.
- Mavrogeni SI, Gotsis ED, Markussis V, T2 relaxation time study of iron overload in β-thalassemia. MAGMA. 1998; 6(1):7–12.
- Anderson LJ, Wonke B, Prescott E, Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet. 2002; 360(9332):516–520.
- Di Bartolomeo P, Santarone S, Di Bartolomeo E, Long term results of survival in patients with thalassemia major treated with bone marrow transplantation. Am J Hematol. 2008; 83(7):528–530.
- Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The protocol of the International Committee on Oral Chelators. Hemoglobin. 2006; 30(2):239–249.
- Kolnagou A, Michaelides Y, Kontos C, Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone. Hemoglobin. 2008; 32(1–2):17–28.
- Peng CT, Chow KC, Chen JH, Safety monitoring of cardiac and hepatic systems in β‐thalassaemia patients with chelating treatment in Taiwan. Eur J Haematol. 2003; 70(6):392–397.
- Pennell DJ, Berdoukas V, Karagiorga M, Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006; 107(9):3738–3744.
- Kontoghiorghes GJ. Prospects for introducing deferiprone as potent pharmaceutical antioxidant. Front Biosci. 2009; E1:161–178.